TABLE 2.

Survival outcomes in obiltoxaximab treatment studies

Treatment dose (mg/kg)	% Survivalb (no. surviving/total no.), P value, for study:
	R1	R2	M1	M2	M3	M4a
						Arm 1	Arm 2
Placebo	0 (0/9)d, NA	0 (0/13), NA	14.3 (2/14)	6.3 (1/16)	12.5 (2/16)	0 (0/17)
1	37.5 (3/8)d, 0.0327	16.7 (2/12), 0.1187	—	—	—	—	—
4	73.3 (11/15), 0.0012c	33.3 (4/12), 0.0232c	78.6 (11/14), 0.0015c	25.0 (4/16), 0.1074	—	—	—
8	—	69.2 (9/13), 0.0011c	73.3 (11/15), 0.0017c	—	6.3 (1/16), 0.8038	—	—
16	92.9 (13/14), 0.0010c	61.5 (8/13), 0.0013c	—	46.7 (7/15), 0.0068c	—	31.3 (5/16), 0.0085c	35.3 (6/17), 0.0055c
32	—	—	—	—	37.5 (6/16), 0.0599	—	—
Levofloxacin	88.9 (8/9), 0.0011c	—	—	—	—	—	—

^aObiltoxaximab products manufactured at two different facilities were tested in arm 1 and arm 2.

^bOnly animals that were bacteremic prior to treatment were included in the analyses. NA, not applicable; —, dose not tested.

^cStatistical significance at the 0.025 level.

^dOne animal was inadvertently dosed with levofloxacin and excluded from analyses.